Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 16/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 14/20 | 0.41 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201719 | 0.83 | JAK1 (0.38) | — | |
| SCHEMBL2202108 | 0.83 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL2200295 | 0.82 | PARP1 (0.40) | — | |
| SCHEMBL2202799 | 0.78 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL2202806 | 0.78 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 | |
| SCHEMBL1719250 | 0.75 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1L3MBTL4MAPTTDP1 | |
| SCHEMBL1720087 | 0.71 | ACACB (0.41) | L3MBTL3L3MBTL1L3MBTL4MAPTTDP1 | |
| SCHEMBL1719832 | 0.71 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1L3MBTL4MAPTTDP1 | |
| SCHEMBL10207105 | 0.71 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1L3MBTL4MAPTTDP1 | |
| SCHEMBL20922362 | 0.70 | L3MBTL3 (0.67) | L3MBTL3L3MBTL1L3MBTL4MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | L3MBTL3 4146/4885L3MBTL1 4149/4885L3MBTL4 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.